Amicus Therapeutics (FOLD) Set to Announce Earnings on Thursday

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) is scheduled to be releasing its earnings data before the market opens on Thursday, May 9th. Analysts expect Amicus Therapeutics to post earnings of ($0.06) per share for the quarter. Parties that wish to listen to the company's conference call can do so using this link.

Amicus Therapeutics (NASDAQ:FOLD - Get Free Report) last issued its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.05). Amicus Therapeutics had a negative return on equity of 119.46% and a negative net margin of 37.96%. The company had revenue of $115.08 million during the quarter, compared to the consensus estimate of $115.11 million. On average, analysts expect Amicus Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD remained flat at $10.43 on Thursday. 2,576,847 shares of the stock traded hands, compared to its average volume of 3,017,335. Amicus Therapeutics has a 12-month low of $9.70 and a 12-month high of $14.57. The company has a quick ratio of 2.52, a current ratio of 2.88 and a debt-to-equity ratio of 2.42. The stock's 50-day moving average is $11.67 and its 200-day moving average is $11.99. The company has a market cap of $3.09 billion, a price-to-earnings ratio of -20.57 and a beta of 0.80.

Analysts Set New Price Targets

Several analysts have weighed in on FOLD shares. JPMorgan Chase & Co. cut their price objective on Amicus Therapeutics from $21.00 to $19.00 and set an "overweight" rating on the stock in a research report on Monday, March 18th. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $22.00 price target on shares of Amicus Therapeutics in a research note on Thursday, February 29th.

Insider Activity

In related news, CEO Bradley L. Campbell sold 4,167 shares of the company's stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $14.00, for a total value of $58,338.00. Following the sale, the chief executive officer now owns 871,219 shares in the company, valued at approximately $12,197,066. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. In other Amicus Therapeutics news, insider David Michael Clark sold 4,427 shares of the firm's stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $14.00, for a total transaction of $61,978.00. Following the completion of the sale, the insider now directly owns 253,664 shares in the company, valued at approximately $3,551,296. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Bradley L. Campbell sold 4,167 shares of the company's stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $14.00, for a total transaction of $58,338.00. Following the completion of the transaction, the chief executive officer now owns 871,219 shares in the company, valued at approximately $12,197,066. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 48,108 shares of company stock worth $662,605. Insiders own 2.10% of the company's stock.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.